BUSINESS
How tainted cough syrups slip through India’s broken drug oversight
India’s drug regulation system is split between the central and state governments, which often leads to confusion and weak enforcement.
BUSINESS
Indian patients demand transparency, willing to pay more for certified quality says FICCI & EY-Parthenon report
The findings, outlined in the ‘True Accountable Care’ report released (FICCI) and EY-Parthenon on Thursday, underscore a growing clamour for a national framework that establishes clear quality standards, moving the system beyond informal, word-of-mouth-based decisions.
BUSINESS
Roche faces setback as Delhi high court clears Natco Pharma's low cost generic Risdiplam
The court dismissed Roche’s plea for an injunction, citing public interest and the need for affordable access to the drug, which currently retails at over ₹600,000 per bottle under Roche’s brand name Evrysdi.
BUSINESS
Cough syrup deaths: Old regulatory failures resurface as CDSCO calls for ‘strict quality control’
The directive is similar to the one issued after India-made cough syrups were blamed for deaths of children in Gambia and Uzbekistan even as Coldrif toll climbs to 22 after two more children die
BUSINESS
Health adtech player Indegene rides Trump pharma shakeup with AI-driven outreach
'Whenever the pharma industry is under pressure, those are better times for us,' says CEO Manish Gupta
BUSINESS
Weight-loss drug Mounjaro is India's second-highest selling pharma brand
Mounjaro recorded sales of Rs 85 crore in September. Analysts say user-friendly pen formulation helped build the momentum, expected to get a further boost from GST cuts
BUSINESS
USFDA to fast-track review of generics tested and made in US, but do Indian drugmakers need to worry?
The move is part of a broader push to onshore pharmaceutical production and reduce reliance on foreign suppliers, particularly from India and China.
BUSINESS
Centre proposes Rs 5,000 crore R&D booster for Pharma and MedTech: Can it drive innovation?
The initiative, backed by a total financial outlay of Rs 5,000 Crore (nearly $600 million) spanning from FY 2023-24 to FY 2029-30, is designed to shift the life sciences economy from a volume-driven, cost-based generic manufacturing hub to an innovation-centric global competitor.
BUSINESS
Wockhardt applies to seek USFDA nod for ‘miracle’ antibiotic Zaynich
The Mumbai-based company is eyeing a US launch in FY27, marking a pivotal moment for Indian pharma innovation.
BUSINESS
Aditya Birla Education Trust expands mental health & education outreach, touches 3.8 million lives
The push comes as nearly 150 million Indians grapple with stress, anxiety, and depression, yet less than 25% seek help, according to ABET’s latest impact report.
BUSINESS
Indegene acquires BioPharm to boost AI-powered pharma marketing
The deal, executed through Indegene’s US subsidiary ILSL Inc., aims to strengthen the company’s omnichannel and media offerings by integrating BioPharm’s precision marketing expertise with Indegene’s data and analytics platforms.
BUSINESS
Generic drug approvals in US poised for a rise, Indian drugmakers continue to dominate
USFDA approvals are vital for India, which exported $10 billion worth of generic medicines to US in FY25
BUSINESS
Somerset Indus Capital Partners exits Apex Hospitals with 4x return
Somerset’s investment in Apex began in May 2019, during which the hospital group tripled its revenue and doubled its workforce, expanding access to quality healthcare across Tier 2 and Tier 3 cities in Rajasthan.
BUSINESS
Fertility services firm Gaudium IVF re-files IPO with Sebi with a higher OFS portion
The offer now comprises a fresh issue of up to 1.13 crore equity shares and an offer for sale (OFS) of up to 94.94 lakh shares by Dr. Khanna.
BUSINESS
Fresh Trump tariffs, what is at stake for Indian pharma, and the playbook to survive
Imported generics have so far managed to escape Trump’s glare likely due to their critical role in keeping US healthcare costs in check. However, Indian pharma is not waiting for the axe to fall, and experts say a multi-pronged defence strategy by key players is already in motion.
BUSINESS
Lupin to acquire VISUfarma for euro 190 million, expanding European specialty footprint
In 2024, VISUfarma, backed by GHO Capital, reported a revenue of 48.1 million. It operates in all major European markets, including Italy, the UK, Spain, Germany, and France
BUSINESS
Sun Pharma may face tariff turbulence in US but HSBC sees limited earnings risk
HSBC outlines several mitigation strategies for Sun Pharma, including shifting manufacturing to CDMO partners with US-based plants.
BUSINESS
Trump’s 100% drug tariff: A mixed bag for India’s CRDMO industry
“Few Indian pharma companies with exposure to non-U.S. domiciled branded formulation or innovator drug companies, who in turn export to the U.S., may face challenges,” said Deepak Jotwani, VP & Sector Head, ICRA.
BUSINESS
Generic medicines exempted from Trump’s 100% pharma tariffs, but uncertainty continues
While generic drugs are exempted from the latest action, companies still face uncertainty over tariffs due to an investigation by the US government under Section 232 to see whether pharma imports pose a threat to national security.
BUSINESS
Greying India fuels adult diaper market boom, homegrown Friends leads the way
Unlike baby diapers, dominated by FMCG giants such as P&G, Unicharm and Kimberly-Clark, the Rs 1,200-crore adult diaper segment is commanded by Friends with over a 50% market share
BUSINESS
Alkem launches pertuzumab biosimilar in India for treatment of breast cancer
In the pivotal phase 3 clinical trial, Alkem’s pertuzumab biosimilar, developed by its biotech subsidiary, demonstrated equivalence in efficacy, safety, and immunogenicity to the reference product of the innovator, the company said in a press release.
BUSINESS
Senior care market poised to triple in a decade, turning the space into the next big investment idea
Rising life expectancy, smaller families and growing willingness among seniors to spend on care are creating conditions for a market that could expand several times over in the coming decade.
BUSINESS
Stryker expands India R&D with new innovation centre in Bengaluru
The Whitefield centre will house cross-functional teams and advanced labs focused on robotics, artificial intelligence, digital innovation, and product security, the company said Thursday.
BUSINESS
Dr. Agarwal’s says merger valuation structured through fair and transparent process
The swap ratio—23 AHCL shares (Re 1 face value) for every 2 AEHL shares (Rs 10 face value)—was based on independent valuations by PwC and Bansi Mehta & Co., using globally accepted methods and market price trends, says company
